Tissue Regenix Group plc (AIM:TRX)

Market Cap	21.01M
Revenue (ttm)	22.88M
Net Income (ttm)	-569.52K
Shares Out	71.23M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,235,135
Average Volume	54,635
Open	29.05
Previous Close	29.50
Day's Range	29.00 - 30.00
52-Week Range	28.65 - 75.00
Beta	0.93
RSI	27.02
Earnings Date	Jun 9, 2025

About Tissue Regenix Group

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 82
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: TRX

Financial Performance

In 2024, Tissue Regenix Group's revenue was $28.65 million, a decrease of -2.87% compared to the previous year's $29.49 million. Losses were -$713,000, -58.38% less than in 2023.

Financial numbers in USD